Yahoo Finance Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...
Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 447,448 shares of the company.
Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the development of novel RNA therapeutics for the treatment of various diseases. The company's proprietary technologies include lipid-mediated nucleic acid delivery systems and RNA constructs, which are used to develop therapies for diseases with high unmet medical need.
Over the past year, Pad Chivukula has sold a total of 102,000 shares and has not purchased any shares. This recent sale is part of a broader trend observed within the company, where there have been 10 insider sells and no insider buys over the past year.
Shares of Arcturus Therapeutics Holdings Inc were trading at $40.01 on the day of the transaction. The company has a market cap of approximately $1.116 billion.
According to the GF Value, the intrinsic value of the stock is estimated at $46.14, suggesting that the stock is Modestly Undervalued with a price-to-GF-Value ratio of 0.87. The GF Value is calculated based on historical trading multiples, an adjustment factor from GuruFocus, and future business performance estimates provided by Morningstar analysts.
This insider sale might be of interest to investors tracking insider behaviors and the valuation levels of Arcturus Therapeutics Holdings Inc, considering the current market conditions and the company's valuation metrics.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
